Literature DB >> 2787751

Inhibition of T cell response with peptides is influenced by both peptide-binding specificity of major histocompatibility complex molecules and susceptibility of T cells to blocking.

P V Lehmann1, F Cardinaux, E Appella, S Muller, F Falcioni, L Adorini, Z A Nagy.   

Abstract

Synthetic peptides corresponding to sequences 46-62 and 51-62 of mouse lysozyme and 46-61 of hen egg-white lysozyme (HEL) were used as competitors in a variety of T cell responses. The competitors, according to their binding specificity for major histocompatibility complex (MHC) were expected to inhibit T cell responses restricted to I-Ak, but not those restricted to I-Ad, I-Ek molecules. In competition experiments with T cell hybridomas, the poor binder I-Ed molecule required 10- to 15-fold higher competitor concentrations than the good binder I-Ak molecule to achieve 50% inhibition of antigen presentation. Similarly, the nonresponder state of H-2d mice to HEL peptide 46-61 could be overcome by increasing the immunizing dose, and proliferative T cell responses to different antigens in association with a variety of class II MHC molecules could be blocked by the mouse lysozyme and HEL peptides. Thus, the capability of some and failure of other MHC molecules to bind certain peptides appeared quantitative, rather than of an all or none nature, in these experimental systems. The susceptibility of uncloned T cell lines to peptide competitors was found to decrease with time. Lines maintained by repeated restimulation with antigen and APC, but without exogenous interleukin 2, acquired resistance within weeks. In contrast, T cell clones retained their susceptibility to peptide competitors over a long period of time. The latter data raise the possibility that a competition between ubiquitous (self) peptides and foreign antigen may result in the selection of T cells that have high avidity for the activating antigen-MHC complex, and are thus relatively resistant to competition at the level of antigen presentation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787751     DOI: 10.1002/eji.1830190617

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Analysis of human T-cell epitopes in the 19,000 MW antigen of Mycobacterium tuberculosis: influence of HLA-DR.

Authors:  A Faith; C Moreno; R Lathigra; E Roman; M Fernandez; S Brett; D M Mitchell; J Ivanyi; A D Rees
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

2.  G1/S cell cycle arrest provoked in human T cells by antibody to CD26.

Authors:  Kei Ohnuma; Tomonori Ishii; Satoshi Iwata; Osamu Hosono; Hiroshi Kawasaki; Masahiko Uchiyama; Hirotoshi Tanaka; Tadanori Yamochi; Nam H Dang; Chikao Morimoto
Journal:  Immunology       Date:  2002-11       Impact factor: 7.397

3.  Analysis of the basis of resistance and susceptibility of CD4+ T cells to human immunodeficiency virus (HIV)-gp120 induced anergy.

Authors:  A Faith; R E O'Hehir; M Malkovsky; J R Lamb
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

4.  Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone.

Authors:  M H Wauben; C J Boog; R van der Zee; I Joosten; A Schlief; W van Eden
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

5.  How much of virus-specific CD8 T cell reactivity is detected with a peptide pool when compared to individual peptides?

Authors:  Wenji Zhang; Ioana Moldovan; Oleg S Targoni; Ramu A Subbramanian; Paul V Lehmann
Journal:  Viruses       Date:  2012-10-29       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.